Alivus Life Sciences Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a net profit of ₹1,967.45 million for the quarter. Total income for the quarter stood at ₹7,019.04 million, while total expenses were ₹4,399.30 million. The results were approved by the Board of Directors on October 29, 2026.
Alivus Life Sciences Reports Q2 and H1 FY27 Unaudited Financial Results
Alivus Life Sciences Limited has announced its unaudited financial results for the second quarter and the half year ended September 30, 2026. The Board of Directors, at a meeting held on October 29, 2026, approved these results.
Financial Performance for the Quarter Ended September 30, 2026:
- Total Income: ₹7,019.04 million
- Total Expenses: ₹4,399.30 million
- Profit Before Tax: ₹2,619.74 million
- Tax Expenses: ₹652.29 million
- Net Profit for the period: ₹1,967.45 million
- Total Comprehensive Income: ₹1,976.43 million
Financial Performance for the Half Year Ended September 30, 2026:
- Total Income: ₹13,647.19 million
- Total Expenses: ₹8,905.22 million
- Profit Before Tax: ₹4,741.97 million
- Tax Expenses: ₹1,173.76 million
- Net Profit for the period: ₹3,568.21 million
- Total Comprehensive Income: ₹3,580.27 million
Key Balance Sheet Highlights as at September 30, 2026:
- Total Assets: ₹43,419.36 million
- Total Equity: ₹36,312.86 million
- Total Liabilities: ₹7,106.50 million
The company has also reported earnings per equity share (face value of ₹2 each) as ₹16.02 (Basic) and ₹15.98 (Diluted) for the quarter ended September 30, 2026. The unaudited financial results and the limited review report of the auditor have been made available on the company’s website, www.alivus.com.
Source: BSE
